[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-rupture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-rupture":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100566639","physician-modified-endovascular-grafts-for-the-treatment-of-juxtarenal-aortic-aneurysms-100566639",false,"NCT06657794","Physician Modified Endovascular Grafts for the Treatment of Juxtarenal Aortic Aneurysms","Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms","PMEG","Inclusion Criteria:\n\nAll patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:\n\n1. Patient is ≥ 18 years of age\n2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)\n3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form\n4. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:\n\n   1. An aneurysm with a maximum diameter of ≥ 5.5 cm for male (≥ 5.0 cm for female) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements\n   2. Aneurysm with a history of growth \\> 0.5 cm in 6 months\n   3. Saccular aneurysm deemed at significant risk for rupture\n   4. Symptomatic aneurysm\n   5. Ruptured aneurysm\n5. Patient has patent iliac or femoral arteries, with or without the use of conduit, that will allow endovascular access with the physician modified endovascular graft.\n6. Patient has a suitable non-aneurysmal proximal aortic neck of ≥ 2 mm inferior to the most distal renal artery ostium.\n7. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥ 15mm. The resultant repair should preserve patency in at least one hypogastric artery.\n8. Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32 mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.\n9. Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.\n10. Patient has juxtarenal aortic neck angulation ≤ 60°\n11. Target branch vessel diameter ≥ 5 mm.\n12. Patient must be willing to comply with all required follow-up exams.\n\nExclusion Criteria:\n\nPatients that meet ANY of the following are not eligible for enrollment into the study:\n\n1. Patient has a mycotic aneurysm or has an active systemic or local infection that may increase the risk of endovascular infection\n2. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)\n3. Patient has a major surgical or interventional procedure, not related to the endovascular repair, planned within +\u002F- 30 days of the AAA repair.\n4. Patient has history of an aortopathic connective tissue disease (e.g. Marfan's or Ehler's-Danlos syndrome).\n5. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.\n6. Patient has known allergy or intolerance to stainless steel, nitinol or gold (gold-coated tungsten).\n7. Patient has a body habitus that would inhibit X-ray visualization of the aorta\n8. Patient has a limited life expectancy of less than 1 year\n9. Patient is currently participating in another investigational device or drug clinical trial\n10. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pretreatment, required treatment, and post-treatment procedures and evaluations.\n11. Thrombus or excessive calcification within the neck of the aneurysm\n12. Branch vessel stenosis ≥ 80%\n13. Patient treatable on label with FDA approved EVAR or FEVAR device and can wait for device availability.\n14. Subject is willing and eligible to enroll in a manufacturer-sponsored study at the investigational site, or the subject is willing and eligible to participate in a study with a manufacturer-made device at another institution.","ALL","18 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of the clinical investigation \"Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms\" is to assess the use of the Physician-Modified Endovascular Grafts to repair juxtarenal aneurysms in high-risk subjects considered to be unsuitable candidates for open surgical repair, have limited or no other options for treatment, and having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device:\n\n* acutely (i.e., treatment success and technical success);\n* at 30 days (i.e., the rate of major adverse events (MAE)); and\n* at 6 months, 12 months and annually to 5 years (i.e., the proportion of treatment group subjects that achieve and maintain treatment success).",[27,28],"Juxtarenal Aortic Aneurysm","Aortic Rupture","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":33},"2025-02-17",{"date":37,"type":21},"2030-12-31",{"name":39,"class":40},"The Cleveland Clinic","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":67,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":41},"100434493","developing-a-decision-instrument-to-guide-abdominal-pelvic-ct-imaging-of-blunt-trauma-patients-100434493","NCT04937868","Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients","NEXUS AP CT","Inclusion Criteria:\n\nBlunt trauma patients who undergo abdominal-pelvic CT imaging during their initial trauma evaluation in the emergency department.\n\nExclusion Criteria:\n\nNone",{"count":50,"type":21},12000,"OBSERVATIONAL","Unrecognized abdominal and pelvic injuries can result in catastrophic disability and death. Sporadic reports of \"occult\" injuries have generated concern, and physicians, fearing that they may miss such an injury, have adopted the practice of obtaining computed tomography on virtually all patients with significant blunt trauma. This practice exposes large numbers patients to dangerous radiation at considerable expense, while detecting injuries in a small minority of cases.\n\nExisting data suggest that a limited number of criteria can reliably identify blunt injury victims who have \"no risk\" of abdominal or pelvic injuries, and hence no need for computed tomography (CT), without misidentifying any injured patient. It is estimated that nationwide implementation of such criteria could result in an annual reduction in radiographic charges of $75 million, and a significant decrease in radiation exposure and radiation induced malignancies.\n\nThis study seeks to determine whether \"low risk\" criteria can reliably identify patients who have sustained significant abdominal or pelvic injuries and safely decrease CT imaging of blunt trauma patients. This goal will be accomplished in the following manner:\n\nAll blunt trauma victims undergoing computed tomography of the abdomen\u002Fpelvis in the emergency department will undergo routine clinical evaluations prior to radiographic imaging. Based on these examinations, the presence or absence of specific clinical findings (i.e. abdominal\u002Fpelvic\u002Fflank pain, abdominal\u002Fpelvic\u002Fflank tenderness, bruising abrasions, distention, hip pain, hematuria, hypotension, tachycardia, low or falling hematocrit, intoxication, altered sensorium, distracting injury, positive FAST imaging, dangerous mechanism, abnormal x-ray imaging) will be recorded for each patient, as will the presence or absence of abdominal or pelvic injuries. The clinical findings will serve as potential imaging criteria. At the completion of the derivation portion of the study the criteria will be examined to find a subset that predicts injury with high sensitivity, while simultaneously excluding injury, and hence the need for imaging, in the remaining patients. These criteria will then be confirmed in a separate validation phase of the study.\n\nThe criteria will be considered to be reliable if the lower statistical confidence limit for the measured sensitivity exceeds 98.0%. Potential reductions in CT imaging will be estimated by determining the proportion of \"low-risk\" patients that do not have significant abdominal or pelvic injuries.",[54,55,56,57,58,59,60,61,62,28,63,64,65,66],"Abdominal Injury","Pelvic Fracture","Genital Hemorrhage","Lumbar Spine Injury","Hip Injuries","Liver Injury","Spleen Injury","Renal Injury","Diaphragm Injury","Aortic Dissection","Bowel Disease","Vascular System Injuries","Sacral Fracture",[68,69,70,71,72,73,74,75,76],"Blunt trauma","Abdominal injury","Pelvic injury","Spine injury","Genital injury","Vascular injury","Hip injury","Computed tomography","Decision instrument","2026-01-09",{"date":79,"type":33},"2026-01-13",{"date":81,"type":33},"2018-01-15",{"date":83,"type":21},"2027-06-15",{"name":85,"class":40},"University of California, Los Angeles",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100593932","phase-4-life-saving-treatment-with-dry-plasma-for-massive-bleeding-in-an-pre-hospital-setting-100593932","NCT07012863","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age.\n* Patients who lack clinical signs of major bleeding.",{"count":94,"type":21},650,[96],"PHASE4","The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.\n\nResearchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.",[99,28,100,101,102,103],"Bleeding","Gastrointestinal Hemorrhage","Obstetric Bleeding","Blunt Injury","Penetrating Injury","NOT_YET_RECRUITING","2025-09-16",{"date":107,"type":33},"2025-09-17",{"date":109,"type":21},"2026-01-01",{"date":111,"type":21},"2027-09-30",{"name":113,"class":114},"Vastra Gotaland Region","OTHER_GOV"]